Abstract Objective: To analyze the effect of brexpiprazole on metabolic parameters and body weight in adults with schizophrenia, including clinically relevant
Abstract Objectives The objective of this study was to evaluate the long‐term safety and tolerability of flexible‐dose brexpiprazole adjunct to
Abstract Brexpiprazole, a serotonin-dopamine activity modulator, is a partial agonist at 5-HT1A and dopamine D2 receptors, and antagonist at 5-HT2A and noradrenaline α1B and α2C receptors, all at similar
Implications/conclusions: Differences in tolerability profiles regarding activation and sedation have implications in terms of selecting the optimal antipsychotic for
Abstract Background: Brexpiprazole has previously demonstrated efficacy in acute schizophrenia trials. The objective of this trial was to assess the efficacy,
Abstract Objective: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). להמשך
Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator. We evaluated the effects of adjunctive treatment with brexpiprazole on sleep disturbances in
Highlights • Many patients with MDD experience symptoms that impair functioning and productivity. • Brexpiprazole+ADT was studied in young patients
Abstract Background: Approximately 50% of patients with major depressive disorder do not respond adequately to their antidepressant treatment, underscoring the
Highlights • Brexpiprazole is an adjunctive therapy for treatment of MDD. • Anxiety symptoms are prevalent in MDD and associated
